WO2001081581A2 - Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire - Google Patents

Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire Download PDF

Info

Publication number
WO2001081581A2
WO2001081581A2 PCT/US2001/012865 US0112865W WO0181581A2 WO 2001081581 A2 WO2001081581 A2 WO 2001081581A2 US 0112865 W US0112865 W US 0112865W WO 0181581 A2 WO0181581 A2 WO 0181581A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
group
nos
further provides
acnes
Prior art date
Application number
PCT/US2001/012865
Other languages
English (en)
Other versions
WO2001081581A3 (fr
WO2001081581A9 (fr
Inventor
Yasir A. W. Skeiky
David H. Persing
Jennifer L. Mitcham
Siqing Steven Wang
Ajay Bhatia
Jean-Francois L'maisonneuve
Yanni Zhang
Shyian Jen
Darrick Carter
Original Assignee
Corixa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corporation filed Critical Corixa Corporation
Priority to CA002407352A priority Critical patent/CA2407352A1/fr
Priority to AU2001255524A priority patent/AU2001255524A1/en
Priority to EP01928693A priority patent/EP1278854A2/fr
Priority to JP2001578652A priority patent/JP2004520803A/ja
Publication of WO2001081581A2 publication Critical patent/WO2001081581A2/fr
Publication of WO2001081581A3 publication Critical patent/WO2001081581A3/fr
Publication of WO2001081581A9 publication Critical patent/WO2001081581A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

L'invention concerne les compositions et les procédés pour la thérapie et le diagnostic de l'acné vulgaire et d'autres états apparentés. Les compositions peuvent comprendre une ou plusieurs protéines de Propionibacterium acnes, des fractions immunogènes de celles-ci, ou des polynucléotides qui codent de telles fractions. Selon une variante, une composition thérapeutique peut comprendre un anticorps qui fixe une protéine de Propionibacterium acnes, une cellule présentant un antigène qui exprime une protéine de Propionibacterium acnes, ou une cellule T qui agit spécifiquement sur les cellules exprimant une telle protéine. De telles compositions peuvent être utilisées, par exemple, pour la prévention et/ou le traitement de l'acné.
PCT/US2001/012865 2000-04-21 2001-04-20 Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire WO2001081581A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002407352A CA2407352A1 (fr) 2000-04-21 2001-04-20 Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire
AU2001255524A AU2001255524A1 (en) 2000-04-21 2001-04-20 Compositions and methods for the therapy and diagnosis of acne vulgaris
EP01928693A EP1278854A2 (fr) 2000-04-21 2001-04-20 Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire
JP2001578652A JP2004520803A (ja) 2000-04-21 2001-04-20 尋常性挫瘡の治療および診断のための組成物および方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US19904700P 2000-04-21 2000-04-21
US60/199,047 2000-04-21
US20884100P 2000-06-02 2000-06-02
US60/208,841 2000-06-02
US21674700P 2000-07-07 2000-07-07
US60/216,747 2000-07-07

Publications (3)

Publication Number Publication Date
WO2001081581A2 true WO2001081581A2 (fr) 2001-11-01
WO2001081581A3 WO2001081581A3 (fr) 2002-03-14
WO2001081581A9 WO2001081581A9 (fr) 2003-01-03

Family

ID=27393973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012865 WO2001081581A2 (fr) 2000-04-21 2001-04-20 Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire

Country Status (5)

Country Link
EP (1) EP1278854A2 (fr)
JP (1) JP2004520803A (fr)
AU (1) AU2001255524A1 (fr)
CA (1) CA2407352A1 (fr)
WO (1) WO2001081581A2 (fr)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055104A2 (fr) * 2000-12-21 2002-07-18 Arkagen, Inc. Vaccin contre l'acne
WO2003040172A2 (fr) * 2001-11-09 2003-05-15 Aegera Therapeutics, Inc. Procedes et reactifs destines aux tamis par interaction peptides-bir
EP1391462A1 (fr) * 2001-04-24 2004-02-25 Otsuka Pharmaceutical Co., Ltd. Peptide de liaison a des anticorps de la maladie de crohn et methode d'examen de ladite maladie
WO2003059943A3 (fr) * 2002-01-18 2004-03-11 Karobio Ab Peptides specifiques a la conformation, de liaison de la proteine kinase, procedes et produits associes
DE10232776A1 (de) * 2002-07-18 2004-04-08 Henkel Kgaa Oligonukleotide zum Nachweis von Mikroorganismen
WO2004056853A3 (fr) * 2002-12-23 2004-09-23 Vib Vzw Proteine immunomodulatrice derivee des trypanosomes et ses utilisations
WO2005047313A1 (fr) * 2003-11-14 2005-05-26 Peptide Door Co., Ltd. Peptide ou proteine apte a fixer le lipide a et le lps, adn codant ledit peptide ou ladite proteine et utilisation dudit peptide ou de ladite proteine, adsorbant de lps ou agent de neutralisation de poison de lps
WO2005087929A1 (fr) * 2004-03-15 2005-09-22 Tissugen Pty Ltd Etiologie infectieuse de maladie prostatique et procede d'identification d'agents etiologiques
WO2005106009A2 (fr) * 2004-04-30 2005-11-10 Chiron Srl Clivage par la lactoferrine de proteines neisseriales
JP2006014726A (ja) * 2004-07-01 2006-01-19 Biomay Produktions-& Handels-Ag イエダニ由来のアレルゲン
WO2006099871A1 (fr) * 2005-03-22 2006-09-28 Novozymes A/S Polypeptides et acides nucleiques les codant
WO2007007055A1 (fr) * 2005-07-12 2007-01-18 The University Of Leeds Bacteriophage et utilisations
US7238665B2 (en) * 2003-07-01 2007-07-03 National Taiwan University Peptide marker targeting to nasopharyngeal carcinoma cell and application thereof
JP2008512391A (ja) * 2004-09-07 2008-04-24 ザ バーナム インスティテュート 心臓血管に対して選択的にホーミングするペプチド、ならびに関連する結合体および方法
EP1932852A1 (fr) * 2006-12-15 2008-06-18 Campiani, Giuseppe Peptides liées au taxane originales et utilisations de celles-ci
US7432061B2 (en) * 2002-05-31 2008-10-07 Biozyme, Inc. Assays for measuring matrix metalloproteinase activities
EP2042186A1 (fr) * 2005-01-31 2009-04-01 Vaxinnate Corporation Nouveaux polypeptides se fixant au récepteur 2 (TLR2) de type Toll
US7592009B2 (en) * 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
AU2005221729B2 (en) * 2004-03-15 2009-09-24 Tissugen Pty Ltd Infectious aetiology of prostatic disease and methods to identify causative agents
WO2009105592A3 (fr) * 2008-02-19 2009-12-30 Hogan James J Compositions et procédés pour la détection d'acide nucléique de propionibacterium acnes
WO2010065954A3 (fr) * 2008-12-05 2010-08-05 Abraxis Bioscience, Llc Peptides de liaison à sparc et leurs utilisations
FR2945125A1 (fr) * 2009-05-04 2010-11-05 Ingen Biosciences Methode de diagnostic des infections a propionibacterium acnes
US20110002848A1 (en) * 2003-10-21 2011-01-06 Burnham Institute For Medical Research Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
US20110195911A1 (en) * 2008-03-28 2011-08-11 The United States Of America,As Represented By The Secretary,Department Of Health & Human Services Synthetic analogs of the juxtamembrane domain of igf1r and uses thereof
US20110243960A1 (en) * 2008-12-05 2011-10-06 The Regents Of The University Of California Methods and compositions for treating p. acnes
FR2959229A1 (fr) * 2010-04-21 2011-10-28 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
WO2011143318A3 (fr) * 2010-05-11 2012-01-05 Aveo Pharmaceuticals, Inc. Anticorps anti-fgfr2
US20130244925A1 (en) * 2002-05-28 2013-09-19 Omrix Biopharmaceuticals Inc. Molecules mimicking an autoantibody idiotype and compositions containing same
EP2248533B1 (fr) * 2009-05-05 2013-11-06 Universitätsklinikum Freiburg Polypeptide dérivé de l'antérocoque et son utilisation pour la vaccination
US8637635B2 (en) 2004-09-07 2014-01-28 Lianglin Zhang Peptides that selectively home to heart vasculature and related conjugates and methods
US8703914B2 (en) 2000-02-28 2014-04-22 Novartis Ag Heterologous expression of neisserial proteins
US9328143B2 (en) 2008-10-22 2016-05-03 Vect-Horus Peptide derivatives and use thereof as carriers for molecules in the form of conjugates
CN106167820A (zh) * 2016-05-19 2016-11-30 胤安国际（辽宁）基因科技股份有限公司 鉴定或辅助鉴定痤疮丙酸杆菌的专用引物及其应用
US9889165B2 (en) 2016-04-21 2018-02-13 Naked Biome, Inc. Compositions and methods for treatment of skin disorders
US10336790B2 (en) * 2014-03-10 2019-07-02 Rensselaer Polytechnic Institute Anti-microbial peptides and method for designing novel anti-microbial peptides
US10364473B2 (en) 2012-03-17 2019-07-30 The Regents Of The University Of California Fast diagnosis and personalized treatments for acne
US10584344B2 (en) 2014-06-17 2020-03-10 Crown Laboratories, Inc. Genetically modified bacteria and methods for genetic modification of bacteria
WO2020099352A3 (fr) * 2018-11-12 2020-07-09 Imcyse Sa Peptides immunogènes dotés de nouveaux motifs d'oxydoréductase
US10745447B2 (en) 2015-09-28 2020-08-18 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
WO2021119756A1 (fr) * 2019-12-20 2021-06-24 PYC Therapeutics Limited Nouveaux procédés d'administration cellulaire
WO2021165543A1 (fr) 2020-02-21 2021-08-26 Origimm Biotechnology Gmbh Traitement immunitaire prophylactique et thérapeutique de propionibacterium acnes
US11155578B2 (en) * 2016-02-17 2021-10-26 Pepticom Ltd. Peptide agonists and antagonists of TLR4 activation
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation
US20230176480A1 (en) * 2021-12-02 2023-06-08 Samsung Electronics Co., Ltd. Polypeptide, photoresist composition including the same, and method of forming pattern using the same
US11905523B2 (en) 2019-10-17 2024-02-20 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
US11903910B2 (en) 2017-09-26 2024-02-20 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders
US11976096B2 (en) 2023-09-26 2024-05-07 Ginkgo Bioworks, Inc. Antibody-evading virus vectors

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149099A1 (fr) 2010-05-27 2011-12-01 Kenichiro Hasumi Peptide antigénique et son utilisation
JP6628285B2 (ja) * 2013-03-14 2020-01-08 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ａｌｓ関連ジアミノ酸リピート含有タンパク質
JP2022507968A (ja) * 2018-11-26 2022-01-18 ノース カロライナ ステイト ユニヴァーシティ 宿主細胞タンパク質の捕捉のためのペプチドリガンド

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CORIXA CORPORATION - POWERING THE IMMUNE SYSTEM, [Online] XP002180961 Retrieved from the Internet: URL:http://www.corixa.com/default.asp?pid= release_detail&year=2001&ID=9> [retrieved on 2001-10-18] *
DATABASE EMBL Entry AA809595 16 February 1998 (1998-02-16), NATIONAL CANCER INSTITUTE: "nj43f09.s1 NCI_CGAP_Pr9 Homo sapiens cDNA clone" XP002281294 accession no. ACCESSION NUMBER AA809595 *
MISKIN J E ET AL: "PROPIONIBACTERIUM ACNES, A RESIDENT OF LIPID-RICH HUMAN SKIN, PRODUCES A 33 KDA EXTRACELLULAR LIPASE ENCODED BY GEHA" MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 143, no. 5, 1997, pages 1745-1755, XP000952640 ISSN: 1350-0872 *
STEINER B ET AL: "CLONING AND SEQUENCING OF THE HYALURONATE LYASE GENE FROM PROPIONIBACTERIUM ACNES" CANADIAN JOURNAL OF MICROBIOLOGY, OTTAWA, CA, vol. 43, no. 4, 1997, pages 315-321, XP000952641 ISSN: 0008-4166 *

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150898B2 (en) 2000-02-28 2015-10-06 Glaxosmithkline Biologicals Sa Heterologous expression of Neisserial proteins
US8703914B2 (en) 2000-02-28 2014-04-22 Novartis Ag Heterologous expression of neisserial proteins
WO2002055104A3 (fr) * 2000-12-21 2003-03-13 Arkagen Inc Vaccin contre l'acne
WO2002055104A2 (fr) * 2000-12-21 2002-07-18 Arkagen, Inc. Vaccin contre l'acne
EP1391462A1 (fr) * 2001-04-24 2004-02-25 Otsuka Pharmaceutical Co., Ltd. Peptide de liaison a des anticorps de la maladie de crohn et methode d'examen de ladite maladie
EP1391462A4 (fr) * 2001-04-24 2004-09-15 Otsuka Pharma Co Ltd Peptide de liaison a des anticorps de la maladie de crohn et methode d'examen de ladite maladie
WO2003040172A2 (fr) * 2001-11-09 2003-05-15 Aegera Therapeutics, Inc. Procedes et reactifs destines aux tamis par interaction peptides-bir
WO2003040172A3 (fr) * 2001-11-09 2004-03-11 Aegera Therapeutics Inc Procedes et reactifs destines aux tamis par interaction peptides-bir
WO2003059943A3 (fr) * 2002-01-18 2004-03-11 Karobio Ab Peptides specifiques a la conformation, de liaison de la proteine kinase, procedes et produits associes
US20130244925A1 (en) * 2002-05-28 2013-09-19 Omrix Biopharmaceuticals Inc. Molecules mimicking an autoantibody idiotype and compositions containing same
US10040869B2 (en) * 2002-05-28 2018-08-07 Omrix Biopharmaceuticals Ltd. Molecules mimicking an autoantibody idiotype and compositions containing same
US7432061B2 (en) * 2002-05-31 2008-10-07 Biozyme, Inc. Assays for measuring matrix metalloproteinase activities
DE10232776A1 (de) * 2002-07-18 2004-04-08 Henkel Kgaa Oligonukleotide zum Nachweis von Mikroorganismen
WO2004056853A3 (fr) * 2002-12-23 2004-09-23 Vib Vzw Proteine immunomodulatrice derivee des trypanosomes et ses utilisations
US7238665B2 (en) * 2003-07-01 2007-07-03 National Taiwan University Peptide marker targeting to nasopharyngeal carcinoma cell and application thereof
US20110002848A1 (en) * 2003-10-21 2011-01-06 Burnham Institute For Medical Research Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
US8598316B2 (en) * 2003-10-21 2013-12-03 Sanford-Burnham Medical Research Institute Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
WO2005047313A1 (fr) * 2003-11-14 2005-05-26 Peptide Door Co., Ltd. Peptide ou proteine apte a fixer le lipide a et le lps, adn codant ledit peptide ou ladite proteine et utilisation dudit peptide ou de ladite proteine, adsorbant de lps ou agent de neutralisation de poison de lps
WO2005087929A1 (fr) * 2004-03-15 2005-09-22 Tissugen Pty Ltd Etiologie infectieuse de maladie prostatique et procede d'identification d'agents etiologiques
AU2005221729B2 (en) * 2004-03-15 2009-09-24 Tissugen Pty Ltd Infectious aetiology of prostatic disease and methods to identify causative agents
EP1725662A4 (fr) * 2004-03-15 2008-03-05 Tissugen Pty Ltd Etiologie infectieuse de maladie prostatique et procede d'identification d'agents etiologiques
US8334114B2 (en) 2004-04-30 2012-12-18 Novartis Ag Lactoferrin cleavage of neisserial proteins
WO2005106009A3 (fr) * 2004-04-30 2006-03-30 Chiron Srl Clivage par la lactoferrine de proteines neisseriales
WO2005106009A2 (fr) * 2004-04-30 2005-11-10 Chiron Srl Clivage par la lactoferrine de proteines neisseriales
JP2006014726A (ja) * 2004-07-01 2006-01-19 Biomay Produktions-& Handels-Ag イエダニ由来のアレルゲン
JP2008512391A (ja) * 2004-09-07 2008-04-24 ザ バーナム インスティテュート 心臓血管に対して選択的にホーミングするペプチド、ならびに関連する結合体および方法
US8637635B2 (en) 2004-09-07 2014-01-28 Lianglin Zhang Peptides that selectively home to heart vasculature and related conjugates and methods
EP2042186A1 (fr) * 2005-01-31 2009-04-01 Vaxinnate Corporation Nouveaux polypeptides se fixant au récepteur 2 (TLR2) de type Toll
WO2006099871A1 (fr) * 2005-03-22 2006-09-28 Novozymes A/S Polypeptides et acides nucleiques les codant
WO2007007055A1 (fr) * 2005-07-12 2007-01-18 The University Of Leeds Bacteriophage et utilisations
JP2010505444A (ja) * 2006-10-10 2010-02-25 エコレ ポルイテクフニクエ フェデラレ デ ラウサンネ 軟骨にターゲティングするためのポリペプチドリガンド及びその使用方法
US7592009B2 (en) * 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
EP1932852A1 (fr) * 2006-12-15 2008-06-18 Campiani, Giuseppe Peptides liées au taxane originales et utilisations de celles-ci
WO2009105592A3 (fr) * 2008-02-19 2009-12-30 Hogan James J Compositions et procédés pour la détection d'acide nucléique de propionibacterium acnes
US20110195911A1 (en) * 2008-03-28 2011-08-11 The United States Of America,As Represented By The Secretary,Department Of Health & Human Services Synthetic analogs of the juxtamembrane domain of igf1r and uses thereof
US9328143B2 (en) 2008-10-22 2016-05-03 Vect-Horus Peptide derivatives and use thereof as carriers for molecules in the form of conjugates
US8445637B2 (en) 2008-12-05 2013-05-21 Abraxis Bioscience, Llc SPARC binding peptides and uses thereof
WO2010065954A3 (fr) * 2008-12-05 2010-08-05 Abraxis Bioscience, Llc Peptides de liaison à sparc et leurs utilisations
US9340769B2 (en) * 2008-12-05 2016-05-17 The Regents Of The University Of California Methods and compositions for treating P. acnes
AU2009322130B2 (en) * 2008-12-05 2013-06-13 Abraxis Bioscience, Llc SPARC binding peptides and uses thereof
US8821836B2 (en) 2008-12-05 2014-09-02 Abraxis Bioscience, Llc SPARC binding peptides and uses thereof
RU2491085C2 (ru) * 2008-12-05 2013-08-27 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Sparc-связующие пептиды и их применение
US20110243960A1 (en) * 2008-12-05 2011-10-06 The Regents Of The University Of California Methods and compositions for treating p. acnes
CN102281890A (zh) * 2008-12-05 2011-12-14 阿布拉西斯生物科学有限责任公司 Sparc结合肽及其应用
WO2010128232A3 (fr) * 2009-05-04 2011-01-06 Ingen Biosciences Méthode de diagnostic des infections à propionibacterium acnes
FR2945125A1 (fr) * 2009-05-04 2010-11-05 Ingen Biosciences Methode de diagnostic des infections a propionibacterium acnes
EP2248533B1 (fr) * 2009-05-05 2013-11-06 Universitätsklinikum Freiburg Polypeptide dérivé de l'antérocoque et son utilisation pour la vaccination
WO2011131896A3 (fr) * 2010-04-21 2012-01-19 Vect-Horus Derives peptidiques, leur preparation et leurs utilisations comme vecteurs
FR2959229A1 (fr) * 2010-04-21 2011-10-28 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
AU2011244107B2 (en) * 2010-04-21 2015-07-16 Centre National De La Recherche Scientifique Peptide derivatives, preparation thereof and uses thereof as vectors
EA022422B1 (ru) * 2010-04-21 2015-12-30 Вект-Орус Пептидные производные, их получение и применение
CN103119052A (zh) * 2010-04-21 2013-05-22 维克塔-霍洛斯公司 肽衍生物、其制备和用途
WO2011143318A3 (fr) * 2010-05-11 2012-01-05 Aveo Pharmaceuticals, Inc. Anticorps anti-fgfr2
US8481688B2 (en) 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
US10364473B2 (en) 2012-03-17 2019-07-30 The Regents Of The University Of California Fast diagnosis and personalized treatments for acne
US11692229B2 (en) 2012-03-17 2023-07-04 The Regents Of The University Of California Fast diagnosis and personalized treatments for acne
US10336790B2 (en) * 2014-03-10 2019-07-02 Rensselaer Polytechnic Institute Anti-microbial peptides and method for designing novel anti-microbial peptides
US11202449B2 (en) 2014-03-10 2021-12-21 Rensselaer Polytechnic Institute Anti-microbial peptides and method for designing novel anti-microbial peptides
US10584344B2 (en) 2014-06-17 2020-03-10 Crown Laboratories, Inc. Genetically modified bacteria and methods for genetic modification of bacteria
US11208438B2 (en) 2015-09-28 2021-12-28 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
US10745447B2 (en) 2015-09-28 2020-08-18 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
US11155578B2 (en) * 2016-02-17 2021-10-26 Pepticom Ltd. Peptide agonists and antagonists of TLR4 activation
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation
US11207357B2 (en) 2016-04-21 2021-12-28 Symbiome, Inc. Compositions and methods for treatment of skin disorders
US9889165B2 (en) 2016-04-21 2018-02-13 Naked Biome, Inc. Compositions and methods for treatment of skin disorders
US10293007B2 (en) 2016-04-21 2019-05-21 Naked Biome, Inc. Compositions and methods for treatment of skin disorders
CN106167820A (zh) * 2016-05-19 2016-11-30 胤安国际（辽宁）基因科技股份有限公司 鉴定或辅助鉴定痤疮丙酸杆菌的专用引物及其应用
US11903910B2 (en) 2017-09-26 2024-02-20 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders
WO2020099352A3 (fr) * 2018-11-12 2020-07-09 Imcyse Sa Peptides immunogènes dotés de nouveaux motifs d'oxydoréductase
CN113015541A (zh) * 2018-11-12 2021-06-22 易姆赛斯股份公司 具有新氧化还原酶基序的免疫原性肽
US11905523B2 (en) 2019-10-17 2024-02-20 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
WO2021119756A1 (fr) * 2019-12-20 2021-06-24 PYC Therapeutics Limited Nouveaux procédés d'administration cellulaire
WO2021165543A1 (fr) 2020-02-21 2021-08-26 Origimm Biotechnology Gmbh Traitement immunitaire prophylactique et thérapeutique de propionibacterium acnes
US20230176480A1 (en) * 2021-12-02 2023-06-08 Samsung Electronics Co., Ltd. Polypeptide, photoresist composition including the same, and method of forming pattern using the same
US11976096B2 (en) 2023-09-26 2024-05-07 Ginkgo Bioworks, Inc. Antibody-evading virus vectors

Also Published As

Publication number Publication date
CA2407352A1 (fr) 2001-11-01
JP2004520803A (ja) 2004-07-15
WO2001081581A3 (fr) 2002-03-14
AU2001255524A1 (en) 2001-11-07
EP1278854A2 (fr) 2003-01-29
WO2001081581A9 (fr) 2003-01-03

Similar Documents

Publication Publication Date Title
EP1278854A2 (fr) Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire
US7935353B2 (en) Compounds and methods for diagnosis and immunotherapy of tuberculosis
JP5053497B2 (ja) 乳癌の治療および診断のための組成物および方法
WO2003033515A1 (fr) Compositions et methodes pour le traitement et le diagnostic de l'acne vulgaire
EP1196565A2 (fr) Compositions et techniques de therapie et de diagnostic du cancer du poumon
WO2001040269A2 (fr) Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
KR20070121814A (ko) 클라미디아 감염에 대비한 백신
EP1278855A2 (fr) Composes et procedes pour le traitement et le diagnostic d'une infection a i chlamydia /i
AU2001273128C1 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6844325B2 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
AU2001273128A1 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20020022591A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2000078960A2 (fr) Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
WO2001073031A2 (fr) Compositions et methodes destinees au traitement et au diagnostic du cancer de l'ovaire
US6686447B1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
US7517952B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6914132B1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003020108A2 (fr) Compositions et procedes destines a diagnostiquer et a traiter une infection par le virus de l'herpes simplex
WO2002012332A2 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du colon
US20020111308A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
US20020137911A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
US20030008299A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001090154A2 (fr) Compositions et procedes therapeutiques et diagnostiques du cancer ovarien
WO2002012329A2 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer de la tete et du cou
KR20030008369A (ko) 유방암의 치료 및 진단용 조성물 및 방법

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 578652

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2407352

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001928693

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: TABLE 2, DESCRIPTION, ADDED (10 PAGES)

WWP Wipo information: published in national office

Ref document number: 2001928693

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2001928693

Country of ref document: EP